retatrutide trial news Retatrutide, an experimental weight-loss drug, has not been approved by the FDA Retatrutide Achieves Up to 30.3%

To support overall health during treatment, its important to consider supplements that address these gaps

According to the Employee Benefit Research Institute, simulation modeling indicates that expanding GLP1 coverage can raise employer health premiums by 6% to nearly 14% annually, depending on how widely the drugs are made available and how consistently members remain on therapy

When gastric emptying is slowed by GLP-1 medications, this gastric distension lasts longer , leading to pressure, bloating, and prolonged fullness

Studies in the pig showed GLP-1 inhibited pancreatic secretion induced by hypoglycemia (central neural stimulation) but not that due to vagal nerve stimulation (126)

Read full article Introduction Many patients beginning GLP 1 medications such as Semaglutide or Tirzepatide want clear expectations about how quickly results will appear